Analyst consensus rating
Century Therapeutics Analyst Rating: none
Direct answer
Century Therapeutics's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.75.
Forecast evidence checked October 27, 2026.
Get free Century Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.45
- Average price target
- $4.75
- High price target
- $8.00
- Low price target
- $2.00
- Low target gap
- +37.9%
- Target upside
- +227.6%
- High target gap
- +451.7%
- Target range width
- 413.8%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- October 27, 2026
- Valid through
- November 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Century Therapeutics?
Century Therapeutics has a verified none consensus. The same dataset has an average price target of $4.75.
How far are Century Therapeutics's low and high targets from the recorded price?
The low target implies +37.9%, while the high target implies +451.7%.
How many analysts are included in Century Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is Century Therapeutics's target upside or downside calculated?
The average target of $4.75 is divided by the recorded price of $1.45, then one is subtracted to produce +227.6%. This does not guarantee a future return.
When was Century Therapeutics's analyst forecast verified?
The data was verified on 2026-10-27. The dataset is valid through 2026-11-03.